The Effects of Physical Activity and Low-Dose Ibuprofen on Cognitive Function in Cancer Patients
A Phase II Study of the Effects of Physical Activity and Low-Dose Ibuprofen on Cognitive Function in Cancer Patients Undergoing Chemotherapy
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
New York
-
Rochester, New York, Forenede Stater, 14642
- University of Rochester
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Must report cognitive difficulties of 3 or higher on a 0-10 scale
- Must provide informed consent
- Be able to read English
- Have a primary diagnosis of cancer
- Be able to swallow medication
- Women of child-bearing potential must not be pregnant or become pregnant during the 6 week study
- Agree not to take NSAIDs during the 6 week intervention period
- Be scheduled to receive at least 2 additional cycles of oral or IV chemotherapy over the 42-day study period.
- Must have the approval of their treating physician to begin the exercise program and receive the ibuprofen
- Must be over 18 years of age
Exclusion Criteria:
- Currently taking a consistent dosage of a NSAID at least 3 days a week for the last 3 months that is over 400mg daily
- Have an allergy to ibuprofen
- Be identified as in active or maintenance stage of exercise behavior as assessed by the single-item exercise stages of change short form
- have physical limitations that contraindicate participation in sub-maximal physiological fitness testing or a low to moderate home-based walking and progressive resistance program
- have a history of peptic ulcer disease within the last 12 months
- Diagnosed with a neurodegenerative disease
- Had a myocardial infraction within the past 6 months
- Patients with a neutropenic episode during the first cycle of chemotherapy or at high risk for a neutropenic episode during future chemotherapy cycles at the treating physicians discretion
- Have confirmed metastatic disease to the central nervous system
- Have been hospitalized for a major psychiatric illness within the last 5 years
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Faktoriel opgave
- Maskning: Dobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Aktiv komparator: Placebo and Home-Based Exercise
200mg placebo (taken twice a day at least 8 hours apart) for a period of 6 weeks and a progressive walking and resistance band exercise program called Exercise for Cancer Patient (EXCAP) for a period of 6 weeks.
|
A progressive walking and resistance band exercise program called Exercise for Cancer patient (EXCAP) for a 6 week period
Andre navne:
200mg BID and 8 hours apart
Andre navne:
|
|
Aktiv komparator: Ibuprofen 200mg BID, Home-Based Exercise
200mg ibuprofen (taken twice a day at least 8 hours apart) and a progressive walking and resistance band exercise program called Exercise for Cancer Patient (EXCAP) for a period of 6 weeks.
|
A progressive walking and resistance band exercise program called Exercise for Cancer patient (EXCAP) for a 6 week period
Andre navne:
200 mg BID and 8 hours apart
Andre navne:
|
|
Placebo komparator: Placebo
200mg placebo (taken twice a day at least 8 hours apart) for a period of 6 weeks.
|
200mg BID and 8 hours apart
Andre navne:
|
|
Aktiv komparator: Ibuprofen 200 mg BID
200mg ibuprofen (taken twice a day at least 8 hours apart) for a period of 6 weeks.
|
200 mg BID and 8 hours apart
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Memory Performance as Assessed by Computerized Cognitive Assessment - Mean Values by Arm
Tidsramme: Baseline and 6 weeks
|
Memory performances (percent correct across delays) as assessed by the objective CANTAB delayed matching to sample task Percentage correct range (0 to 100) Higher percentage is better
|
Baseline and 6 weeks
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Cognitive Functioning Score as Assessed by FACT-COG Questionnaire - Perceived Cognitive Impairment (PCI) - Mean Values by Arm
Tidsramme: Baseline and 6 weeks
|
Cognitive functioning score as assessed subjectively by a psychometrically validated instrument (FACT-COG) - Perceived Cognitive Impairment (PCI) (min=0, max=116) Higher Score is better
|
Baseline and 6 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Lægemidlers fysiologiske virkninger
- Molekylære mekanismer for farmakologisk virkning
- Agenter fra det perifere nervesystem
- Enzymhæmmere
- Analgetika
- Sensoriske systemagenter
- Analgetika, ikke-narkotisk
- Antirheumatiske midler
- Cyclooxygenase-hæmmere
- Anti-inflammatoriske midler
- Ibuprofen
- Anti-inflammatoriske midler, ikke-steroide
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 31416
- K07CA168886 (U.S. NIH-bevilling/kontrakt)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .